Table 3. AUC, sensitivity, specificity, PPV and NPV of IgA-gH/gL and EBV DNA in IgA-VCA-negative NPC patients in the training cohort.
| Test | AUC (95%) | pa | Sensitivity | pb | Specificity | pb | PPV | pc | NPV | pc | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | |||||||
| gH/gL | 0.879 (0.820-0.937) | 78.1 | 63.6-92.4 | 82.3 | 77.0-87.6 | 42.0 | 29.5-54.5 | 96.0 | 93.0-99.0 | |||||
| EBV DNA | 0.750 (0.637-0.863) | 53.1 | 35.8-70.4 | 94.9 | 91.8-98.0 | 63.0 | 44.8-81.2 | 92.6 | 89.0-96.2 | |||||
| gH/gL vs. EBV DNA | 0.003 | 0.021 | <0.001 | NS | NS | |||||||||
PPV, positive predictive value; NPV, negative predictive value; NS, not significant; gH/gL, enzyme-linked immunosorbent assay detection of IgA antibodies against EBV glycoprotein complex gH/gL; VCA, immunofluorescence assay for IgA antibodies against viral capsid antigen; EBV DNA, qPCR test for plasma circulating EBV DNA.
Z test.
McNemar's paired-sample test.
Chi-squared test